A diverse bunch of neurodegenerative diseases, tauopathies are marked by a range of clinical manifestations and of neuropathological hallmarks. According to a study published September 29 in Nature, ...

Zooming in on a single disease and studying it intensely is often the most productive route to finding treatments. But there's no easy way to distinguish among people living with any of the primary ...

Alzheimer's disease (AD) currently afflicts over 6 million Americans with expected financial burdens for long-term care and hospices for this population exceeding 350 billion. These numbers threaten ...

A study shows that about a quarter of people with clinically diagnosed mild or moderate Alzheimer’s disease (AD) have only minimal β-amyloid (Aβ) deposition on autopsy. And nearly half of patients ...

Researchers know that ApoE4 and Trem2 can worsen neurodegeneration in mouse models of tauopathy. Do these proteins conspire to exacerbate pathology? It turns out that ApoE4 causes much of the damage ...

The spread of tau protein aggregates in the brain—a process that drives cognitive decline in Alzheimer’s disease and frontotemporal dementia—has been studied with a model that incorporates human ...

The first tau biomarkers that have the potential to identify types of frontotemporal lobar degeneration (FTLD) in living patients and facilitate design of clinical trials to evaluate prospective ...

The emergence of human induced pluripotent stem cell (hiPSC) technology has led to the development of several useful 3D in vitro modelling platforms for the study of tauopathy. However, most of these ...

(A–D) After the end of treatments, PS19 mice did not present differences in the working memory (Y-maze test) (A) (CIT/PBS, n = 11; STZ/PBS, n = 14; CIT/AMY, n = 10; CIT/AMY, n = 12), recognition ...

Figure 5. Gene expression profiling revealed various patterns of changes in PFC and hippocampus of P301S mice at different ages. “Here we used the PS19 (P301S) mouse model of tauopathies to ...